Clinical trials: Liver Tumor
Hepatocellular Carcinoma
A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
To determine if IMC-A12 given in combination with Sorafenib is safe and effective for participants with advanced liver cancer.
- Trial name
- NCT00906373
- Testing
- IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg), IMC-A12 (cixutumumab) - 20 mg/kg, Sorafenib
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma
BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre Post-market Follow-up Study.
The primary objective of the study is to confirm safety and efficacy of BioPearl™ microspheres loaded with doxorubicin in the treatment of patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- BIOPEARL-FIRST (NCT04231929)
- Testing
- Chemoembolization
- Where
- 3 sites in Belgium
- Sponsor
- Terumo Europe N.V.
Breast Cancer, Lung Cancer
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor…
- Conditions
- Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer
- Trial name
- TRT-001 (NCT02960594)
- Testing
- INO-1400, INO-9012, INO-1401
- Where
- 6 sites in United States
- Volunteers
- 93 people
- Sponsor
- Inovio Pharmaceuticals
Neoplasms, Carcinoma, Hepatocellular
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of…
- Conditions
- Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms
- Trial name
- NCT06687941
- Testing
- AST-201
- Where
- 4 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Aptamer Sciences, Inc.
Carcinoma, Hepatocellular
A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
This randomized, placebo-controlled, multicenter study will evaluate the efficacy and safety of GC33 (RO5137382) in previously treated patients with unresectable advanced or metastatic hepatocellular carcinoma.
- Trial name
- NCT01507168
- Testing
- GC33
- Where
- 57 sites in United States, Belgium and 11 more
- Volunteers
- 185 people
- Sponsor
- Hoffmann-La Roche
Cancer, Drug Induced Liver Injury
Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy
Cancer has moved from the tenth place to the second one over the last 100 years, being inferior to only cardiovascular diseases in morbidity and mortality.
- Trial name
- NCT05789797
- Testing
- Remaxol
- Where
- 5 sites in Russia
- Volunteers
- 368 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Liver Metastases, Colorectal Carcinoma
An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.
Estimation of the concordance of Tc 99m localization in liver metastases from colorectal carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.
- Trial name
- NCT03029988
- Testing
- Tilmanocept (Technetium Tc 99m tilmanocept Injection), SPECT/CT Imaging
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Navidea Biopharmaceuticals
Liver Cirrhosis, Liver Cancer
Multi-analyte Blood Test Clinical Trial
The objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance.
- Conditions
- Liver Cirrhosis, Liver Cancer, HCC, Hepatocellular Carcinoma
- Trial name
- LIVER-1 (NCT05199259)
- Testing
- Multi-analyte Blood Test
- Where
- 7 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Helio Genomics
Breast Cancer, Lung Cancer
Sample Collection for Ongoing Research and Product Evaluation Study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer
- Trial name
- SCORE (NCT07318051)
- Where
- United States
- Volunteers
- 9,600 people
- Sponsor
- Natera, Inc.
Hepatocellular,Carcinoma
Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients
This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial. Patients with no tumor lesions one month after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment…
- Trial name
- NCT01489566
- Testing
- Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma
This study will evaluate the safety, efficacy, and activity of patupilone in patients with advanced unresectable and/or metastatic hepatocellular carcinoma based on tumor response using modified RECIST criteria.
- Trial name
- NCT00273312
- Testing
- Patupilone
- Where
- 7 sites in United States, Hong Kong and 2 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Hepatocellular
Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.
This study investigates the safety and efficacy of the combination therapy with BAY86-9766 and sorafenib in patients with liver cancer. Safety will be determined by laboratory and other evaluations.
- Trial name
- BASIL (NCT01204177)
- Testing
- BAY86-9766 MEK Inhibitor + Sorafenib
- Where
- 15 sites in Hong Kong, Singapore and 2 more
- Volunteers
- 70 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients
This trial is a single-arm, open, multicenter phase II clinical study.Subjects can only enter this study after they meet the inclusion and exclusion criteria.Into subjects will accept HLX10 + HLX04 intravenous infusion, every two…
- Trial name
- NCT03973112
- Testing
- HLX10 3mg/kg, HLX04 5mg/kg, HLX04 10mg/kg
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Shanghai Henlius Biotech
Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC)
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
The goal of this interventional clinical study is to learn the safety and preliminary efficacy of XH001 injection (Personalized mRNA tumor neoantigen vaccine) combined with standard adjuvant treatment in treating patients with…
- Conditions
- Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular Carcinoma (HCC), Gastric Cancer (GC)
- Trial name
- NCT07594964
- Testing
- XH001 Injection, mFOLFIRINOX Treatment Regimen
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Shenzhen Xinhe Biomedical
Hepatocellular Carcinoma
the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma
There are two studies included in this protocol. One is an open-label Phase Ⅱ study . The other is a multi-center, double-blind, randomized, phase III study .
- Trial name
- HCC (NCT05408221)
- Testing
- Rulonilimab+Lenvatinib
- Where
- 5 sites in China
- Volunteers
- 576 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Liver Cancer
Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors
This is a open-label, single center, cohort study to determine the efficacy and safety of IM83 CAR-T cells in patients with advanced Liver Tumors.
- Trial name
- NCT05123209
- Testing
- IM83 CAR-T cells, The second-line treatment of liver cancer
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial
This clinical trial aims to systematically evaluate the clinical performance and accuracy of the HepaAiQ test kit, a multi-gene methylation assay based on PCR with fluorescent probe detection.
- Trial name
- NCT06842563
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Singlera Genomics Inc.
Carcinoma, Hepatocellular, Carcinoma, Renal Cell
Regulatory Post Marketing Surveillance Study on Nexavar®
This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar
- Trial name
- NCT01012011
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- South Korea
- Volunteers
- 2,845 people
- Sponsor
- Bayer
Ovarian Cancer, Hepatocellular Carcinoma
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
- Conditions
- Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03836352
- Testing
- DPX-Survivac, Cyclophosphamide, Pembrolizumab
- Where
- 23 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Hepatocellular Cancer, Liver Cancer
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of OMP-54F28 when combined with sorafenib. OMP-54F28 will be administered IV on Day 1 of each 21-day cycle.
- Trial name
- NCT02069145
- Testing
- OMP-54F28 with Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.